Peer-reviewedCC BY-NC-ND 4.0Australian Prescriber
Vanzacaftor, tezacaftor and deutivacaftor fixed-dose combination for cystic fibrosis
Related
- CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant
- Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del -gating and F508del -residual function genotypes: results from an open-label extension study
- Early nutritional management of cystic fibrosis infants born with meconium ileus
- Constrictive pericarditis in cystic fibrosis: a case report of an emerging cardiovascular complication successfully managed with off-pump pericardiectomy
BibTeX
@article{anon2026vanzacaftor,
title = {{Vanzacaftor, tezacaftor and deutivacaftor fixed-dose combination for cystic fibrosis}},
journal = {Australian Prescriber},
year = {2026},
month = oct,
doi = {10.18773/austprescr.2026.036},
url = {https://doi.org/10.18773/austprescr.2026.036},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Vanzacaftor, tezacaftor and deutivacaftor fixed-dose combination for cystic fibrosis
PY - 2026
DA - 2026/10/01
JO - Australian Prescriber
DO - 10.18773/austprescr.2026.036
UR - https://doi.org/10.18773/austprescr.2026.036
SN - 0312-8008
SN - 1839-3942
ER -